Study of a new pill for high-risk myelofibrosis
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial is testing a new pill for people with intermediate or high-risk myelofibrosis, a type of bone marrow cancer. It aims to see if the drug can help manage the disease and offer a new treatment option for those who may have limited choices.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with myelofibrosis, including primary (PMF) or those that developed from other blood diseases (PPV-MF or PET-MF).
- Your spleen is enlarged, which can be felt by your doctor or seen on a scan.
- You have not had an active cancer for at least 5 years, except for some skin cancers or a condition called carcinoma in situ.
- You are not currently taking part in another clinical trial for a new drug or device.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new tablet, Flonoltinib, for people with medium-to-high risk myelofibrosis whose prior JAK inhibitor treatment stopped working, caused side effects, or wasn't tolerated. The goal is to see if this new drug can help reduce spleen size and improve symptoms.
This trial tests an oral medicine called flonoltinib maleate for people with myelofibrosis. It may help reduce an enlarged spleen and improve symptoms like fatigue and night sweats.
This trial is testing a new drug called WJ01024, which may help treat myelofibrosis. It can be taken alone or with ruxolitinib, a standard treatment for this condition. The study checks safety and how well it works.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This trial tests a new drug called TQ05105 to see if it can help people with a blood-marrow disease called myelofibrosis. The study focuses on patients whose condition is moderate to severe and measures how well the drug works and how safe it is.
This study tests an experimental pill called PRT12396 for people with myeloproliferative neoplasms (MPN). It aims to see if the drug is safe and helps control the disease.
Hear when a new MF trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.